UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease

Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease manifests as muscle weakness and can become life-threatening in severe instances.